Search company, investor...

Cleveland BioLabs

cbiolabs.com

Founded Year

2003

Stage

PIPE | IPO

Total Raised

$6M

Market Cap

0.00B

Revenue

$0000 

About Cleveland BioLabs

Cleveland BioLabs (NASDAQ: CBLI) is a biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. Cleveland BioLabs combines proven scientific expertise and depth of knowledge about products' mechanisms of action into a passion for developing drugs to save lives.

Headquarters Location

73 High Street

Buffalo, New York, 14203,

United States

716-849-6810

Missing: Cleveland BioLabs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cleveland BioLabs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cleveland BioLabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cleveland BioLabs is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Cleveland BioLabs Patents

Cleveland BioLabs has filed 26 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Hepatotoxins
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2018

12/8/2020

Radiation health effects, Radiobiology, Radiation therapy, Radiation protection, Digestive system

Grant

Application Date

11/21/2018

Grant Date

12/8/2020

Title

Related Topics

Radiation health effects, Radiobiology, Radiation therapy, Radiation protection, Digestive system

Status

Grant

Latest Cleveland BioLabs News

Global Biodefense Market Report to 2030 - Featuring Altimmune, Emergent BioSolutions, SIGA Technologies and Ichor Medical Systems Among Others - ResearchAndMarkets.com

Nov 21, 2022

Cleveland Biolabs Inc. The market growth is attributed to the increasing government initiatives to strengthen national biodefense mechanisms and the rising research and development activities for developing newer biodefense products. The outbreak of the COVID-19 pandemic has led to a significant increase in the demand for biodefense products, such as vaccines, therapeutics, and diagnostics, as healthcare professionals seek to protect themselves and others from the disease. The pandemic has also highlighted the importance of investing in strong biodefense infrastructure, which is expected to drive market growth over the forecast period. The North America region is expected to hold the largest share in the global biodefense market due to the presence of a large number of key players in the region and the increasing government initiatives to strengthen national biodefense mechanisms. For instance, in May 2020, the U.S. Department of Health and Human Services announced an investment of USD 1.6 Billion in Operation Warp Speed, a public-private partnership aimed at accelerating the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. Biodefense comprises medical countermeasures (MCM) and other actions taken to protect people from the effects of biological warfare agents or bioterrorism. Biological warfare agents are microorganisms, such as bacteria, viruses, fungi, and toxins that can be used intentionally to cause death or disease in humans, animals, or plants. Bioterrorism is the intentional release of harmful microorganisms or toxins to cause death or disease in humans, animals, or plants. Some Key Highlights from the Report Among product type segments, anthrax vaccine segment accounted for largest revenue share in 2021 due to growing government initiatives to promote vaccination among public and military personnel. Also, with the recent outbreak of COVID-19, there is a significant demand for vaccines and therapeutics specifically for this disease. The global biodefense market is expected to grow at a CAGR of over 12% during the period of 2021-2031. The U.S. government has been at the forefront of initiatives to develop and procure biodefense products. The U.S. Department of Health and Human Services (HHS) has been the largest procurer of biodefense products, with a budget of over USD 6 billion in 2020. The U.S. government has also initiated several public-private partnerships (PPPs) to develop new vaccines and therapeutics. For instance, the HHS has partnered with Merck & Co., Inc. to develop a new Ebola vaccine. In terms of disease type, inhalation anthrax accounted for largest revenue share in 2021 due to high mortality rate associated with the disease. According to the Centers for Disease Control and Prevention (CDC), inhalation anthrax is fatal in over 80% of cases. In terms of distribution channel, online segment is expected to grow at a rapid pace during the forecast period. The online sales channel provides easy accessibility to consumers and offers a wide range of products. The hospital pharmacy segment held dominant revenue share in 2020 and the trend is expected to continue during the forecast period due to the increasing number of hospital admissions for infectious diseases. In terms of regions, North America held dominant revenue share in 2020 and the trend is expected to continue during the forecast period due to the growing prevalence of infectious diseases and availability of new vaccines and therapeutics. The biodefense market in Europe is expected to grow at a significant pace during the forecast period. The European Commission has been supporting initiatives to develop new vaccines and therapeutics through its Horizon 2020 program. For instance, the Horizon 2020 program has supported the development of a new vaccine against Crimean-Congo hemorrhagic fever (CCHF). The biodefense market in Asia Pacific is expected to grow at a significant pace during the forecast period. The growing incidence of infectious diseases, such as Zika virus and dengue, is expected to drive the demand for vaccines and therapeutics in the region. The government agencies in the region, such as the National Healthcare Group (NHC) in Singapore, have been investing in research and development of new vaccines and therapeutics. For this report, the author has segmented the global biodefense market based on product type, application, end-use, and region: Product Type Outlook (Revenue, USD Billion; 2019-2030) Anthrax Vaccine Military Hospitals North America

Cleveland BioLabs Frequently Asked Questions (FAQ)

  • When was Cleveland BioLabs founded?

    Cleveland BioLabs was founded in 2003.

  • Where is Cleveland BioLabs's headquarters?

    Cleveland BioLabs's headquarters is located at 73 High Street, Buffalo.

  • What is Cleveland BioLabs's latest funding round?

    Cleveland BioLabs's latest funding round is PIPE.

  • How much did Cleveland BioLabs raise?

    Cleveland BioLabs raised a total of $6M.

  • Who are the investors of Cleveland BioLabs?

    Investors of Cleveland BioLabs include Centrecourt, JGB Management, Sunrise Equity Partners, F. Berdon and Co., SDS Capital Partners and 18 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.